Search

Bacillary angiomatosis is a rather frequent infectious pathology appearing mainly in the skin but can also affect the liver, spleen, heart, bones, lungs, muscles, central nervous system and other organs. The localization of the lesion in the oral cavity is rather rare, as it is evident in the literature. Bacillary angiomatosis can be clinically similar to the Kaposi's sarcoma and histologically confused with angiosarcoma, epitheloid hemangioma and pyogenic granuloma. A case of bacillary angiomatosis of the oral cavity in an immuno-competent patient is described. The high tendency to relapse, the capability in migration and to involve several localizations at the same time have induced the authors to deepen the research to exclude the possibility that it could be a Kaposi's sarcoma or a pyogenic granuloma and to get to an accurate diagnosis in order to resolve the disease.

The efficacy and tolerability of the Bacampicillin was evaluated on 80 patients (40 males and 40 females) with infectious pathology. This antibiotic was delivered at different dosage, alone or in association with Fans. The Authors report the statistical results showing the good therapeutical activity, at full dosage, with minor side effects.

A mean plasma concentration curve, with peaks within the first hour and moderate individual variations, was obtained after a single administration of 800 mg of bacampicillin to 5 healthy volunteers. An adequate antibiotic transfer from the circulation to the bronchial apparatus was demonstrated. Treatment of 34 patients suffering from ampicillin-sensitive bacterial diseases permitted clinical cure of all patients, without onset of side-effects. It is concluded that bacampicillin is preferable to oral ampicillin because of its kinetic and tolerance features.

Student's test was used to show that the symptomatological improvement obtained with amoxycillin (Velamox, Zambelletti) in 64% of patients with dental infection was significantly greater (p 0.05) than the 28% improvement given by a tetracycline (Ambramicina P vitaminica, Lepetit) in another group. Attention is also drawn to the fact that all forms of medical management in such cases must be regarded as coadjuvant to the treatment given by the dentist.

A controlled double-blind biometric and an open clinical trial were conducted to determine the therapeutic effectiveness of a new equal-dose w/w association of amoxicillin and flucloxacillin. The following conclusions were drawn. Both antibiotics were present in high serum levels; those of flucloxacillin were higher and more persistent. Analysis of variance on 89 patients pointed to the superiority of the association by comparison with amoxicillin alone. The clinical study made it clear that the broad and complementary spectrum of the association, its synergy, absence of toxicity and good gastric tolerance make it a valuable and effective therapeutic aid, also in presence of germs that produce beta-lactase.

A mixture of amoxycillin, semisynthetic penicillin beta-lactamase susceptible, and flucloxacillin, an isoxazolylpenicillin, in combination 1:1 was tested. This mixture shows real synergic effect "in vitro" on beta-lactamase producing Gram-positive and Gramnegative bacteria and an additive effect on the other microrganisms. Good results have been obtained "in vivo" and a protective effect of flucloxacillin on enzymatic degradation of amoxycillin by beta-lactamase was found.

The tolerance of a new pivampicillin and dicloxacillin association, especially at high doses and during prolonged treatment, was assessed by administering two 600 mg tablets (350 mg pivampicillin + 250 mg dicloxacillin) every 6 or 8 hr (according to the seriousness of the diseases) to 53 patients with acute infection of varying site and aetiology. Microbiological, radiological and blood chemistry data were collected with reference to the disease involved, along with clinical and laboratory data capable of demonstrating the eventual appearance of unwanted side-effects referable to the association. The results showed that the association was therapeutically effective and well tolerated at high doses given over long periods.

Results with pivampicillin, a new ampicillin with complete gastric absorption and capable of producing high tissue levels, in the prevention and treatment of postoperative infection in 31 cases are presented. The antibiotic was effective in 29 cases, 4 of which had a prior history of antibiotic intractability. Side-effects consisted of slight gastric disturbances, with suspension of treatment in 1 case only. No clinically significant changes in the laboratory data were noted.

Clinical research was conducted to evaluate the comparative therapeutic efficacy in respiratory pathology of 800 mg X 2 per diem bacampicillin v. 1000 mg X 2 per diem amoxicillin, both orally administered. The results were more or less identical and are interpreted as indicating the better constant absorption of the precursor, hence its higher concentration gradient that produces a higher antibiotic concentration in the lungs.

In vitro activity of Amoxycillin towards 87 strains of Staphilococcus aureus clinically isolated was analyzed. The 70% of the strains were very sensitive to the antibiotic action. Moreover the growth of the 50% of the strains was inhibited by Amoxycillin concentrations less than 0.20 mcg/ml.